A phase Ib study of proxalutamide (GT0918) in women with androgen receptor-positive metastatic breast cancer.

1019Background: Androgen receptor (AR) is an emerging prognostic marker and therapeutic target in breast cancer. AR is expressed in 60% to 80% of breast cancers. Recent studies have shown the assoc...